

University of Massachusetts Medical School

eScholarship@UMMS

UMass Center for Clinical and Translational
Science Research Retreat

2016 UMass Center for Clinical and
Translational Science Research Retreat

May 20th, 12:30 PM


Structural Activity Relationship Study on Dual PLK1 /BRD4 Inhibitor, BI- 2536

Hailemichael Yosief
University of Massachusetts Boston

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

 Part of the [Biochemistry Commons](#), [Cancer Biology Commons](#), [Medicinal Chemistry and
Pharmaceutics Commons](#), and the [Medicinal-Pharmaceutical Chemistry Commons](#)

Yosief H, Liu S, Buckley DL, Roberts JM, Muthengi AM, Corsini FM, Bradner JE, Zhang W. (2016). Structural Activity Relationship Study on Dual PLK1 /BRD4 Inhibitor, BI- 2536. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2016/posters/97

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](#). This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

Structural Activity Relationship Study on Dual PLK1 /BRD4 Inhibitor, BI- 2536

Hailemichael Yosief¹; Shuai Liu¹, Dennis L Buckley², Justin M Roberts², Alex M Muthengi¹
Francesca M Corsini¹, Bradner E James² and Wei Zhang¹

¹Department of Chemistry, UMass Boston, Boston, Massachusetts

²Department of Medical Oncology, Dana- Farber Cancer Institute, Boston, Massachusetts

Polo-like kinase 1 (PLK1) and BRD4 are two different therapeutic targets in cancer drug discovery. Recently it has been reported that PLK1 inhibitor, **BI-2536**, is also a potent inhibitor of BRD4. The simultaneous inhibition of PLK1 and BRD4 by a single drug molecule is interesting because this could lead to the development of effective therapeutic strategy for different types of disease conditions in which PLK1 and BRD4 are implicated. Structural activity relationship studies has been carried out on BI-2536 to generate analogs with enhanced dual inhibitory activity against BRD4 and PLK1 as well as to render the molecule selective to one target over the other. **UMB101** and **160** have been found to exhibit enhanced dual inhibitory activity with selectivity fold of less than 30, **UMB160** being the most potent dual-kinase bromodomain inhibitor (BRD4 IC₅₀ = 28 nM, PLK1 IC₅₀ = 40 nM). **UMB131** was found to be the most selective PLK1 inhibitor over BRD4.

Contact information

Hailemichael Yosief

Email: hailemich@gmail.com

Phone: 513-746-5717